Free Trial
NASDAQ:ARDS

Aridis Pharmaceuticals (ARDS) Stock Price, News & Analysis

Aridis Pharmaceuticals logo
$0.0001 0.00 (0.00%)
As of 03/13/2025 01:01 PM Eastern

About Aridis Pharmaceuticals Stock (NASDAQ:ARDS)

Key Stats

Today's Range
$0.0001
$0.0001
50-Day Range
N/A
52-Week Range
$0.00
$0.09
Volume
2,895 shs
Average Volume
10,908 shs
Market Capitalization
$5,332.10
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.

Remove Ads
Receive ARDS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aridis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARDS Stock News Headlines

Aridis Provides Corporate Update
Will Tesla's "Robot Revolution" Double The Stock By 2026?
Tesla’s Robot Revolution Has Begun It’s official… Tesla’s robot revolution is underway… By the end of this year, Tesla plans to produce 600 new “Tesla Bots” per week… Tech insiders believe this could be the company’s next core driver of explosive growth. Some even believe it could be the catalyst that would push shares above the $1,000 mark. That’s essentially a 100% increase from today’s price…
Aridis Provides Corporate Update
Aridis Pharmaceuticals Inc (ARDS)
See More Headlines

ARDS Stock Analysis - Frequently Asked Questions

Aridis Pharmaceuticals' stock was trading at $0.0001 at the beginning of the year. Since then, ARDS stock has increased by 0.0% and is now trading at $0.0001.
View the best growth stocks for 2025 here
.

Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($1.94) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by $1.43. The business earned $0.52 million during the quarter.

Aridis Pharmaceuticals (ARDS) raised $28 million in an IPO on Tuesday, August 14th 2018. The company issued 2,000,000 shares at $13.00-$15.00 per share. Cantor acted as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers.

Shares of ARDS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aridis Pharmaceuticals investors own include VBI Vaccines (VBIV), Cidara Therapeutics (CDTX), Daré Bioscience (DARE), BioCardia (BCDA), Moleculin Biotech (MBRX), SCYNEXIS (SCYX) and Inovio Pharmaceuticals (INO).

Company Calendar

Last Earnings
11/10/2021
Today
3/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ARDS
Employees
30
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.09 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
50,388,000
Market Cap
$5,332.10
Optionable
Not Optionable
Beta
9.82
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:ARDS) was last updated on 3/14/2025 by MarketBeat.com Staff
From Our Partners